Dutasteride
| |
| Dutasteride
| |
| Systematic (IUPAC) name | |
| (5α, 17β)-N-{2,5 bis(trifluoromethyl) phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | G04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C27H30F6N2O2 |
| Mol. mass | 528.53 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 60% |
| Protein binding | 99% |
| Metabolism | Hepatic (CYP3A4-mediated) |
| Half life | 5 weeks |
| Excretion | Fecal |
| Therapeutic considerations | |
| Pregnancy cat. |
X(US) Not to be handled by pregnant women |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Dutasteride | |
|
Articles | |
|---|---|
|
Most recent articles on Dutasteride Most cited articles on Dutasteride | |
|
Media | |
|
Powerpoint slides on Dutasteride | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Dutasteride at Clinical Trials.gov Clinical Trials on Dutasteride at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Dutasteride
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Dutasteride Discussion groups on Dutasteride Patient Handouts on Dutasteride Directions to Hospitals Treating Dutasteride Risk calculators and risk factors for Dutasteride
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Dutasteride | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Dutasteride (marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) is a 5-alpha-reductase inhibitor, a drug which inhibits the conversion of testosterone into dihydrotestosterone (DHT). It is used to treat conditions caused by DHT, such as benign prostatic hyperplasia (BPH).
Classification and Method of Action
Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride also belongs to this group. Dutasteride inhibits both isoforms of 5-alpha reductase, while finasteride inhibits only one. But a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH.
Uses
While dutasteride is officially approved to treat enlargement of the prostate gland. Clinical trials for dutasteride as a hair loss drug were undertaken, but called off in late 2002. The reason the trials were called off is not publicly known. Industry sources speculate that Avodart would have been seen as too similar to Propecia to have proved profitable as a hair loss treatment.
In December 2006, Avodart manufacturer GlaxoSmithKline embarked on a new Phase III, six month study in Korea to test the safety, tolerability and effectiveness of a once-daily dose of dutasteride (0.5mg) for the treatment of male pattern baldness in the vertex region of the scalp (types IIIv, IV and V on the Hamilton-Norwood scale).[1] The future impact that this study will have on the FDA's approval or disapproval of Avodart for the treatment of male pattern baldness in the United States is yet to be determined.
See also
External links
- Effectiveness of Dutasteride as a treatment for Male Pattern Baldness, as reported by Science Daily.
- Official site
- http://www.hairlosshelp.com/html/Dutasteride_hair_loss_trials.cfm
- Information on suspended trials for Avodart as a hair loss treatment Accessed 02/09/2006
References
WikiDoc Research Resources for Dutasteride | |
|---|---|
| Articles on Dutasteride | Most recent articles on Dutasteride • Most cited articles on Dutasteride • Review articles on Dutasteride • Articles on Dutasteride in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Dutasteride | Powerpoint slides on Dutasteride • Images of Dutasteride • Photos of Dutasteride • Podcasts & MP3s on Dutasteride • Videos on Dutasteride |
| Evidence Based Medicine Regarding Dutasteride | AND (Cochrane Database Syst Rev[http://worldselectshop.com/?id=9361 Cochrane Collaboration on Dutasteride • Bandolier on Dutasteride • TRIP on Dutasteride |
| Cost Effectiveness of Dutasteride | AND (Cost effectiveness) |
| group5 = Clinical Trials Involving Dutasteride | list5 = Ongoing Trials on Dutasteride at Clinical Trials.gov • Trial results on Dutasteride • Clinical Trials on Dutasteride at Google
| group6 = Guidelines / Policies / Government Resources (FDA/CDC) Regarding Dutasteride
| list6 = US National Guidelines Clearinghouse on Dutasteride • NICE Guidance on Dutasteride • NHS PRODIGY Guidance • FDA on Dutasteride • CDC on Dutasteride
| group7 = Textbook Information on Dutasteride
| list7 = Books and Textbook Information on Dutasteride
| group8 = Pharmacology Resources on Dutasteride
| list8 =
AND (Dose)}} Dosing of Dutasteride • AND (drug interactions)}} Drug interactions with Dutasteride • AND (side effects)}} Side effects of Dutasteride • AND (Allergy)}} Allergic reactions to Dutasteride • AND (overdose)}} Overdose information on Dutasteride • AND (carcinogenicity)}} Carcinogenicity information on Dutasteride • AND (pregnancy)}} Dutasteride in pregnancy • AND (pharmacokinetics)}} Pharmacokinetics of Dutasteride •
| group9 = Genetics, Pharmacogenomics, and Proteinomics of Dutasteride
| list9 =
AND (pharmacogenomics)}} Genetics of Dutasteride • AND (pharmacogenomics)}} Pharmacogenomics of Dutasteride • AND (proteomics)}} Proteomics of Dutasteride
| group10 = Newstories on Dutasteride
| list10 = Dutasteride in the news • Be alerted to news on Dutasteride • News trends on Dutasteride</small>
| group11 = Commentary on Dutasteride
| list11 =
Blogs on Dutasteride
| group12 = Patient Resources on Dutasteride | list12 = Patient resources on Dutasteride • Discussion groups on Dutasteride • Patient Handouts on Dutasteride • Directions to Hospitals Treating Dutasteride • Risk calculators and risk factors for Dutasteride
| group13 = Healthcare Provider Resources on Dutasteride
| list13 =
Symptoms of Dutasteride • Causes & Risk Factors for Dutasteride • Diagnostic studies for Dutasteride • Treatment of Dutasteride
| group14 = Continuing Medical Education (CME) Programs on Dutasteride | list14 = CME Programs on Dutasteride
| group15 = International Resources on Dutasteride | list15 = Dutasteride en Espanol • Dutasteride en Francais
| group16 = Business Resources on Dutasteride | list16 = Dutasteride in the Marketplace • Patents on Dutasteride
| group17 = Informatics Resources on Dutasteride | list17 = List of terms related to Dutasteride
}}de:Dutasterid
fi:Dutasteridi
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
